Investigative and Clinical Urology最新文献

{"title":"Carbon footprints in the urologic field: From diagnosis to surgery.","authors":"Jongsoo Lee, Miho Song, Jae Heon Kim","doi":"10.4111/icu.20250004","DOIUrl":"10.4111/icu.20250004","url":null,"abstract":"<p><p>Climate change and its effects on society represent an increasingly critical concern. The healthcare industry contributes substantially to carbon emissions and bears responsibility for managing its environmental impact. This review examines recent progress, challenges, and future prospects in reducing the carbon footprint of diagnostic urology without compromising patient care, with particular emphasis on imaging. We analyze the environmental effects of urological procedures and devices, along with practices that can minimize greenhouse gas emissions. Promoting sustainability in healthcare requires a comprehensive approach from manufacturing to disposal, including examination of sterilization-related carbon footprints. This work aims to analyze existing literature on urological carbon footprints, focusing on processes and practices within the field.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 2","pages":"106-113"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885924/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567043","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Efficacy of scheduled intravenous acetaminophen administration for catheter-related bladder discomfort in patients after transurethral resection of bladder tumors: A prospective randomized pilot study.","authors":"Tomoya Hatayama, Koji Mita, Yuki Kohada, Kenta Fujiyama, Ryo Tasaka, Akihiro Goriki, Hideki Mochizuki, Nobuyuki Hinata","doi":"10.4111/icu.20240357","DOIUrl":"10.4111/icu.20240357","url":null,"abstract":"<p><strong>Purpose: </strong>Scheduled administration of intravenous acetaminophen improves catheter-related bladder discomfort (CRBD) after urological surgery. However its efficacy for patients undergoing transurethral resection of bladder tumors (TURBT) remains unclear. This study aimed to investigate the efficacy of scheduled administration of intravenous acetaminophen after TURBT.</p><p><strong>Materials and methods: </strong>At the end of surgery, patients in both the control (n=39) and the scheduled administration (n=45) groups received analgesics at the discretion of the anesthesiologists. In the scheduled administration group, intravenous acetaminophen was administered every 4 hours for 12 hours after the surgery. Both groups were administered on-demand analgesics as needed. The primary outcome was CRBD scores, and the secondary outcomes were the face rating scale for lower abdominal pain, administration rates of additional analgesics, durations of bladder catheterization, lengths of postoperative hospital stay, and postoperative complication rate.</p><p><strong>Results: </strong>The scheduled administration group had significantly lower CRBD scores than those of the control group at 8 hours postoperatively (p=0.014), and lower administration rates of additional analgesics 4-8 hours (p=0.029) and 8-12 hours (p=0.027) postoperatively compared to those of the control group. Other secondary outcomes were not significantly different between the groups (all p>0.05). The scheduled administration group did not have postoperative complications related to the scheduled administration of intravenous acetaminophen.</p><p><strong>Conclusions: </strong>Scheduled intravenous acetaminophen administration alleviated postoperative CRBD and reduced the need for additional analgesics in patients who underwent TURBT. These findings can be utilized to improve the quality of postoperative care.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 2","pages":"144-151"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885918/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567074","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Diagnostic value of prostate health index in patients with no index lesion on mpMRI or negative previous combined biopsy.","authors":"Seong Soo Jeon, Wan Song, Minyong Kang, Hyun Hwan Sung, Hwang Gyun Jeon, Byeong Chang Jeong, Seong Il Seo, Jae Hoon Chung","doi":"10.4111/icu.20250007","DOIUrl":"10.4111/icu.20250007","url":null,"abstract":"<p><strong>Purpose: </strong>To assess the effectiveness of the prostate health index (PHI) in patients with no index lesions on multiparametric magnetic resonance imaging (mpMRI) or with negative findings on past prostate biopsy if there was an index lesion on mpMRI.</p><p><strong>Materials and methods: </strong>Patients without an index lesion on MRI or with a negative result on combined biopsy for index lesions were assessed. Patients who underwent transperineal mapping biopsy among those suspected of having prostate cancer (PCa) due to persistently elevated prostate-specific antigen (PSA) levels were analyzed.</p><p><strong>Results: </strong>Of the 291 patients, 82 (28.2%) were diagnosed with PCa. Sixty-five of 291 patients had negative finding in previous combined biopsy. In total, 226 patients did not have any index lesions. The mean age of the PCa group was 64.33±8.88 years and that of the non-cancer group was 59.88±10.26 years (p<0.001). The PHI was 46.75±28.22 in the PCa group and 37.74±17.37 in the non-cancer group (p=0.001), and the prostate volume was 41.52±15.77 mL in the PCa group and 50.78±23.97 mL in the non-cancer group (p=0.001). In multivariate analysis, age (odds ratio [OR] 1.096, p<0.001), PHI (OR 1.021, p=0.005), and prostate volume (OR 0.954, p<0.001) were identified as significant factors for PCa detection. The optimal cutoff value of the PHI for PCa detection was 44.6 and the PHI density (PHID) was 0.88.</p><p><strong>Conclusions: </strong>In patients with elevated PSA levels but no index lesions on mpMRI or negative biopsy findings, PHI and PHID demonstrated significant potential for improving PCa detection.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 2","pages":"124-129"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885919/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567073","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Changes in urologic research from a new perspective: Text mining analysis of publication topics.","authors":"Soohyung Joo, Kun Lu, Jihwan Park, Mi Jung Rho, Yong Hyun Park","doi":"10.4111/icu.20240388","DOIUrl":"10.4111/icu.20240388","url":null,"abstract":"<p><strong>Purpose: </strong>This study aimed to explore the trends in research keywords and topics in the field of urology based on text mining over the recent decades. The investigation looked into changes in frequent subject keywords and the trends in prevailing research topics, as reflected in representative urology journals over recent decades.</p><p><strong>Materials and methods: </strong>A total of 27,129 bibliographic documents were collected from four urology journals, including <i>European Urology</i>, <i>Journal of Urology</i>, <i>BJU International</i>, and <i>World Journal of Urology</i>. The study then examined the changes in the most frequent author keywords over the decades. Moreover, structured topic modeling was employed to identify twenty prevailing research topics in urology and to examine their trends across different periods.</p><p><strong>Results: </strong>The study observed consistently increasing patterns in author keywords and topics related to the prostate and oncology. Conversely, research fields such as pediatrics, male infertility, voiding dysfunction, and cancer biology exhibited a downward trend in urology. Potential factors or reasons underlying these trends were further discussed in this study.</p><p><strong>Conclusions: </strong>This exploratory study uncovered major research topics in the discipline of urology. The findings of this study depict the domain of urology research in recent decades, providing insights for both researchers and clinicians seeking to better understand the research trends in the discipline.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 2","pages":"172-180"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885921/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567047","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy and safety of energy coagulation in radiation-induced hemorrhagic cystitis: A narrative review.","authors":"Wei Chern Khern, Retnagowri Rajandram, Novinth Kumar Raja Ram, Shanggar Kuppusamy","doi":"10.4111/icu.20240288","DOIUrl":"10.4111/icu.20240288","url":null,"abstract":"<p><p>To assess the efficacy and safety of using energy devices as treatment for radiation-induced hemorrhagic cystitis (RHC) and to determine the most suitable energy source, settings and techniques based on laser-tissue interaction. A search of Google Scholar, PubMed, and Web of Science databases was conducted uptil February 2024 to identify studies on use of energy devices for RHC. Additionally, ClinicalTrials.gov and the World Health Organization's ICTRP (International Clinical Trials Registry Platform) were searched for ongoing studies. We identified 10 studies fulfilling the search criteria using modalities including Nd:YAG laser, argon plasma coagulation, 980-nm diode laser, and potassium-titanyl-phosphate (KTP) laser. Across studies (n=137), majority (n=116, 84.7%) of RHC patients achieved hematuria resolution after one treatment session, with mean/median hematuria-free intervals of 11 to 16 months. Six patients (4.4%) were unresponsive and underwent cystectomy/urinary diversion. Total adverse events occurred in patients (30/139, 21.6%), including storage symptoms, recurrent hematuria, bladder stones and urinary retention, among others. Typical laser settings involved low power (<40 W), with either a pulse duration of 2-3 seconds or 10-40 milliseconds; some used continuous wave mode. Other standard practises include selective coagulation employed in a \"painting\" fashion and non-contact mode (3-5 mm). The treatment endpoints were hemostasis, involution of telangiectatic vessels and formation of pale well-circumscribed mucosal ulcer. Energy devices have considerable efficacy and safety to treat RHC patients and can be considered for refractory RHC and as an adjunct after initial management. The various properties of KTP laser confers an advantage over other energy devices.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 2","pages":"97-105"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885922/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567053","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk-adapted scoring model to identify candidates benefiting from adjuvant chemotherapy after radical nephroureterectomy for localized upper urinary tract urothelial carcinoma: A multicenter study.","authors":"Sung Jun Sou, Ja Yoon Ku, Kyung Hwan Kim, Won Ik Seo, Hong Koo Ha, Hui Mo Gu, Eu Chang Hwang, Young Joo Park, Chan Ho Lee","doi":"10.4111/icu.20240323","DOIUrl":"10.4111/icu.20240323","url":null,"abstract":"<p><strong>Purpose: </strong>Adjuvant chemotherapy (AC) is recommended for muscle-invasive or lymph node-positive upper urinary tract urothelial carcinoma (UTUC) after radical nephroureterectomy (RNU). However, disease recurrences are frequently observed in pT1 disease, and AC may increase the risk of overtreatment in pT2 UTUC patients. This study aimed to validate a risk-adapted scoring model for selecting UTUC patients with ≤pT2 disease who would benefit from AC.</p><p><strong>Materials and methods: </strong>We retrospectively analyzed 443 ≤pT2 UTUC patients who underwent RNU. A risk-adapted scoring model was applied, categorizing patients into low- or high-risk groups. Recurrence-free survival (RFS) and cancer-specific survival (CSS) were analyzed according to risk group.</p><p><strong>Results: </strong>Overall, 355 patients (80.1%) and 88 patients (19.9%) were categorized into the low- and high-risk groups, respectively, with the latter having higher pathological stages, concurrent carcinoma <i>in situ</i>, and synchronous bladder tumors. Disease recurrence occurred in 45 patients (10.2%), among whom 19 (5.4%) and 26 (29.5%) belonged to the low- and high-risk groups, respectively (p<0.001). High-risk patients had significantly shorter RFS (64.3% vs. 93.6% at 60 months; hazard ratio [HR] 13.66; p<0.001) and worse CSS (80.7% vs. 91.5% at 60 months; HR 4.25; p=0.002). Multivariate analysis confirmed that pT2 stage and the high-risk group were independent predictors of recurrence and cancer-specific death (p<0.001). Decision curve analysis for RFS showed larger net benefits with our model than with the T stage model.</p><p><strong>Conclusions: </strong>The risk-adapted scoring model effectively predicts recurrence and identifies optimal candidates for AC post RNU in non-metastatic UTUC.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 2","pages":"114-123"},"PeriodicalIF":2.5,"publicationDate":"2025-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11885917/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143567113","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-center, prospective, non-interventional, observational study on the efficacy and safety of Mirabek^® in adult patients with overactive bladder.","authors":"Jee Soo Park, Won Sik Jang, Jongchan Kim, Moon-Hwa Park, Won Sik Ham","doi":"10.4111/icu.20240278","DOIUrl":"10.4111/icu.20240278","url":null,"abstract":"<p><strong>Purpose: </strong>Mirabegron, the first-in-class beta-3 agonist, is the mainstay medication for overactive bladder (OAB). The aim of this study was to investigate the efficacy and safety of generic drugs of mirabegron (Mirabek^®) in adults diagnosed with OAB through a multicenter, prospective, non-interventional observational study.</p><p><strong>Materials and methods: </strong>Adult patients with OAB prescribed Mirabek^® SR Tab. 50 mg for the first time were recruited from hospitals between September 2021 and September 2022. Participants underwent baseline registration followed by two follow-ups at 4- and 8-week intervals. Data on demographics, medical history, OAB symptoms, vital signs, medication administration, and adverse events were collected.</p><p><strong>Results: </strong>Among 1,714 patients, Mirabek^® SR Tab. 50 mg effectively improved OAB symptoms over an 8-week treatment period, with significant differences in symptom improvement between baseline and both 4- and 8-week time points as well as between 4 weeks and 8 weeks. The incidence rate of adverse events was 0.70%; most cases were mild with no severe reactions.</p><p><strong>Conclusions: </strong>This study demonstrated that Mirabek^®, a generic drug of betmiga, is an effective and safe treatment option for adults with OAB. Furthermore, the introduction of generic drug reduced the costs of prescription drugs and expanded the opportunity for many patients to access mirabegron.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"27-35"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729222/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Ablation of IGFBP5 expression alleviates neurogenic erectile dysfunction by inducing neurovascular regeneration.","authors":"Jiyeon Ock, Guo Nan Yin, Fang-Yuan Liu, Yan Huang, Fitri Rahma Fridayana, Minh Nhat Vo, Ji-Kan Ryu","doi":"10.4111/icu.20240325","DOIUrl":"10.4111/icu.20240325","url":null,"abstract":"<p><strong>Purpose: </strong>To investigate the therapeutic potential of eliminating insulin-like growth factor-binding protein 5 (IGFBP5) expression in improving erectile function in mice with cavernous nerve injury (CNI)-induced erectile dysfunction (ED).</p><p><strong>Materials and methods: </strong>Eight-week-old male C57BL/6 mice were divided into four groups: a sham-operated group and three CNI-induced ED groups. The CNI-induced ED groups were treated with intracavernous injections 3 days before the CNI procedure. These injections included phosphate-buffered saline, scrambled control short hairpin RNA (shRNA), or shRNA targeting mouse IGFBP5 lentiviral particles. One week after CNI, erectile function was evaluated and the penile tissue was then harvested for histological examination and western blot analysis. Additionally, the major pelvic ganglia (MPG) and dorsal root ganglia (DRG) were cultured for <i>ex vivo</i> neurite outgrowth assays.</p><p><strong>Results: </strong>Following CNI, IGFBP5 expression in the cavernous tissues significantly increased, reaching its peak at day 7. First, ablation of IGFBP5 expression promotes neurite sprouting in MPG and DRG when exposed to lipopolysaccharide. Second, ablating IGFBP5 expression in CNI-induced ED mice improved erectile function, likely owing to increased neurovascular contents, including endothelial cells, pericytes, and neuronal processes. Third, ablating IGFBP5 expression in CNI-induced ED mice promoted neurovascular regeneration by increasing cell proliferation, reducing apoptosis, and decreasing Reactive oxygen species production. Finally, western blot analysis demonstrated that IGFBP5 ablation attenuated the JNK/c-Jun signaling pathway, activated the PI3K/AKT signaling pathway, and increased vascular endothelial growth factor and neurotrophic factor expression.</p><p><strong>Conclusions: </strong>Ablating IGFBP5 expression enhanced neurovascular regeneration and ultimately improved erectile function in CNI-induced ED mice.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"74-86"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729225/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anti-inflammatory effect of sea buckthorn in an HCl-induced cystitis rat model.","authors":"Hyun Suk Yoon, Juyeon Yu, Shinhoon Kang, Hana Yoon","doi":"10.4111/icu.20240196","DOIUrl":"10.4111/icu.20240196","url":null,"abstract":"<p><strong>Purpose: </strong>Although the mechanism underlying interstitial cystitis/bladder pain syndrome (IC/BPS) remains unclear, oxidative stress is suggested to be implicated in IC/BPS development. Sea buckthorn (SB; <i>Hippophae rhamnoides</i> L.) contains several compounds with antioxidant properties. In addition, intravesical application of hydrochloric acid (HCl) in rats induces histological changes similar to those observed in humans with IC. Therefore, the aim of this study was to evaluate the anti-inflammatory effects of SB in an HCl-induced rat cystitis model.</p><p><strong>Materials and methods: </strong>Twenty 8-week-old female Sprague-Dawley rats were instilled with HCl in their bladders to create an IC/BPS model. The model rats were divided into three groups and orally administrated distilled water (control, n=4), concentrated SB (n=8), or pentosan polysulfate (PPS, n=8) daily. Pathologic inflammation grade (H&E staining), number of mast cells per square millimeter (toluidine blue staining), fibrotic changes (Masson's trichrome staining), and apoptosis (terminal deoxynucleotidyl transferase dUTP nick end labeling staining) of bladder tissue samples were compared among the groups.</p><p><strong>Results: </strong>Compared to the control group, the SB and PPS groups showed reduced edema (5.25±0.96 vs. 2.25±0.46 vs. 2.50±0.54, p=0.004, p=0.005, respectively), number of mast cells (12.5±3.6 vs. 6.8±1.9 vs. 6.6±1.8, p=0.010, p=0.002, respectively), ratio of fibrotic submucosal tissue (63.9%±7.0% vs. 43.6%±9.9% vs. 40.5%±5.2%, p<0.001, p<0.001, respectively), and ratio of apoptotic nucleus (40.7%±11.7% vs. 7.7%±6.5% vs. 5.1%±4.9%, p<0.001, p<0.001, respectively).</p><p><strong>Conclusions: </strong>SB exhibited anti-inflammatory effects comparable to those of PPS in the HCl-induced chemical cystitis model.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"67-73"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729227/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142949032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DRG2 levels in prostate cancer cell lines predict response to PARP inhibitor during docetaxel treatment.","authors":"Jeong Min Lee, Won Hyeok Lee, Seung Hyeon Cho, Jeong Woo Park, Hyuk Nam Kwon, Ji Hye Kim, Sang Hun Lee, Ji Hyung Yoon, Sungchan Park, Seong Cheol Kim","doi":"10.4111/icu.20240263","DOIUrl":"https://doi.org/10.4111/icu.20240263","url":null,"abstract":"<p><strong>Purpose: </strong>Developmentally regulated GTP-binding protein 2 (DRG2) regulates microtubule dynamics and G2/M arrest during docetaxel treatment. Poly ADP-ribose polymerase (PARP) acts as an important repair system for DNA damage caused by docetaxel treatment. This study investigated whether DRG2 expression affects response to PARP inhibitors (olaparib) using prostate cancer cell lines PC3, DU145, LNCaP-FGC, and LNCaP-LN3.</p><p><strong>Materials and methods: </strong>The cell viability and DRG2 expression levels were assessed using colorimetric-based cell viability assay and western blot. Cells were transfected with DRG2 siRNA, and pcDNA6/V5-DRG2 was used to overexpress DRG2. Flow cytometry was applied for cell cycle assay and apoptosis analysis using the Annexing V cell death assay.</p><p><strong>Results: </strong>The expression of DRG2 was highest in LNCaP-LN3 and lowest in DU145 cells. Expressions of p53 in PC3, DU145, and the two LNCaP cell lines were null-type, high-expression, and medium-expression, respectively. In PC3 (DRG2 high, p53 null) cells, docetaxel increased G2/M arrest without apoptosis; however, subsequent treatment with olaparib promoted apoptosis. In DU145 and LNCaP-FGC (DRG2 low), docetaxel increased sub-G1 but not G2/M arrest and induced apoptosis, whereas olaparib had no additional effect. In LNCaP-LN3 (DRG2 high, p53 wild-type), docetaxel increased sub-G1 and G2/M arrest, furthermore olaparib enhanced cell death. Docetaxel and olaparib combination treatment had a slight effect on DRG2 knockdown PC3, but increased apoptosis in DRG2-overexpressed DU145 cells.</p><p><strong>Conclusions: </strong>DRG2 and p53 expressions play an important role in prostate cancer cell lines treated with docetaxel, and DRG2 levels can predict the response to PARP inhibitors.</p>","PeriodicalId":14522,"journal":{"name":"Investigative and Clinical Urology","volume":"66 1","pages":"56-66"},"PeriodicalIF":2.5,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11729229/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143055907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}